ANI Pharma Inc is a specialty pharmaceutical company focused on developing and commercializing a range of high-quality generic and branded prescription products, primarily in the fields of pain management, endocrinology, and complex formulations
The company aims to address the unique needs of patients by leveraging its expertise in drug formulation and development, while also striving to enhance patient access to its medications. ANI Pharma places a strong emphasis on innovation and quality, utilizing advanced technology to create differentiated products that target specific therapeutic areas.
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQANIP)
jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly surpassing analysts' revenue expectations. Revenue surged 45% year-on-year, fueled by continued growth in its Rare Disease segment. Purified Cortrophin Gel led the way with a 42% rise, while the newly added ILUVIEN and YUTIQ products also boosted sales.
The company raised its 2025 outlook, now expecting sales to climb up to 26% and earnings per share to grow as much as 25%.
Overall, the quarter showed strong sales growth and smart investments.
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year revenue guidance of $766 million at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 13.6% above analysts’ consensus estimates.
ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQVTRS).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Amneal (NASDAQAMRX).
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQAMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQANIP) and its peers.
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial sales growth and an optimistic FY 2024 outlook.
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close in Q3 2024.
